Price movement over the last 24 hours
ADMA Biologics Inc vs EOG Resources Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while EOG Resources Inc trades at $138.62 (market cap $71.66B). The key difference: EOG Resources Inc is far larger — about 33.6× ADMA Biologics Inc's market cap, and EOG Resources Inc pays a 3.03% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EOG | |
|---|---|---|
Market Cap | $2.13B | $71.66B |
Sector | Health | Energy |
52-Week High | $20.38 | $149.89 |
52-Week Low | $7.60 | $101.78 |
Enterprise Value | $2.20B | $76.12B |
Dividend Yield | — | 3.03% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EOG Resources trades at $134.54, up 2.88% today, with a bearish technical signal but strong fundamentals including a P/E of 12.72 and net income margin of 23.39%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected August 5, 2026. Recent news highlights strong free cash flow potential and shareholder returns, while analyst consensus is a Buy with a $157 price target.
The outlook for EOG is positive due to robust profitability, consistent earnings beats, and favorable oil price trends. Key risks include volatile energy markets and high capital expenditures. With no sell ratings from analysts and a price target implying 17% upside, the stock presents a compelling opportunity for value-oriented investors despite near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →